Gilead needs some way to fund themselves, but long-shot lottery-like reimbursement based on a monopoly followed by the inevitable politicking to stop Gilead's "gouging" (of which this article is a part of) is not a good system for doing this.
Not that I think pure publicly-funded research is the way forward either, especially if we'd like to increase incentives for science. That current system works in spite of its brokenness only because the people who are there truly care about their work - scaling it up would be disastrous.
But, especially in this case where the boundaries of ownership arise out of no natural phenomenon, we really need to be smoothing out discontinuities, rather than exacerbating them with simplistic approaches and pretending that the betting wisdom of investors (who by construction are abstracted and out of touch from what's actually going on) will achieve the desired result.